Japan has approved its first biosimilar rival to the blockbuster Humira (adalimumab) brand. Mylan is set to market the Fujifilm Kyowa Kirin Biologics biosimilar locally, having already launched the product as Hulio in Europe under a 2018 partnership that was expanded globally in 2019.
Mylan did not immediately respond to Generics Bulletin enquiries over launch plans for the product in Japan.






